[關(guān)鍵詞]
[摘要]
目的 探討注射用丹參多酚酸對內(nèi)囊預(yù)警綜合征進(jìn)展為腦梗死的療效及患者血清S-100β蛋白的影響。方法 2015年1月—2018年12月安陽市第六人民醫(yī)院診治的內(nèi)囊預(yù)警綜合征進(jìn)展為腦梗死患者40例,隨機(jī)分為對照組和治療組。對照組每日靜脈滴注0.9%生理鹽水250 mL;治療組每日靜脈滴注注射用丹參多酚酸0.13 g加入0.9%生理鹽水250 mL。治療前后檢測血清S-100β蛋白水平和應(yīng)用美國國立衛(wèi)生研究院卒中量表(NIHSS)進(jìn)行神經(jīng)功能缺損程度評定。結(jié)果 治療組和對照組在入院第1天(治療前)血清S-100β水平和神經(jīng)功能缺損程度評分無顯著差異;第14天治療組血清S-100β水平和神經(jīng)功能缺損程度評分低于對照組(P<0.05),同時低于同組治療前的相應(yīng)水平(P<0.05);第30天NIHSS評分治療組低于對照組(P<0.05),且顯著低于同組治療前的(P<0.01)。結(jié)論 注射用丹參多酚酸對內(nèi)囊預(yù)警綜合征進(jìn)展為腦梗死的患者具有減輕神經(jīng)膠質(zhì)細(xì)胞損傷,減緩腦梗死進(jìn)展,促進(jìn)神經(jīng)功能修復(fù)的作用。
[Key word]
[Abstract]
Objective To investigate the therapeutic effect of Salvianolic Acids for Injection on the progression of internal capsule warning syndrome to cerebral infarction and the effect on S-100β protein levels in serum. Methods 40 patients with cerebral infarction coming from capsular warning syndrome were randomly divided into two groups. Based on conventional therapy, the control group was treated with 0.9% normal saline 250 mL every day; while in the treatment group, 0.13 g of Salvianolic Acids for Injection and 250 mL of 0.9% normal saline were given intravenously every day.The changes of S-100β protein levels and NIHSS score were compared in the two groups before and after the treatment. Results There was no significant difference in NIHSS score and the level of S-100β protein between the treatment group and the control group on the first day before treatment. After 14 days treatment, the level of S-100β protein and NIHSS score in treatment group were lower than those in control group, also lower than those in the treatment group before treatment (P<0.05); The NIHSS score of treatment group was lower than control group after thirty days(P<0.05), and was significantly lower than scores of treatment group before treatment (P<0.01). Conclusion The Salvianolic Acids for Injection can relieve the damage of neuroglia cells, slow down the progress of cerebral infarction and promote the repair of nerve function in patients with cerebral infarction coming from capsular warning syndrome.
[中圖分類號]
R969.4
[基金項(xiàng)目]